Status:
COMPLETED
Impact of Anti-HLA Donor-specific Antibodies in ABO-incompatible Kidney Transplantation
Lead Sponsor:
University Hospital, Toulouse
Conditions:
Kidney Transplant
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
It was previously suggested an improvement of graft survival in ABO/HLA incompatible kidney transplantation (KT) compared with HLA (human leukocyte antigen) incompatible transplantation. Here, the inv...
Detailed Description
The investigators propose to analyze the clinical, biological and histological course of kidney function, but also to investigate the T and B cells population after KT in ABO incompatible, ABO/HLA inc...
Eligibility Criteria
Inclusion
- Patient receiving a KT and followed at least one year in Toulouse Hospital
- Patient who have signed informed consent
- \> 18 years old
Exclusion
- Patient under protective measures
- Patients treated for cancer, infectious or immune disease by molecules that could interfere with lymphocyte populations : Interleukin 6 (IL6) blockers, Programmed cell death 1(PD1) and the cytotoxic T-lymphocyte-associated antigen 4 (CTL4) blockers.
- Immunosuppressive treatments withdrawal - Patient in chronic dialysis
- Ongoing pregnancy or pregnancy in the past year
- Past of splenectomy
Key Trial Info
Start Date :
February 6 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 5 2018
Estimated Enrollment :
58 Patients enrolled
Trial Details
Trial ID
NCT03423901
Start Date
February 6 2018
End Date
May 5 2018
Last Update
August 20 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital
Toulouse, France, 31059